Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Age 18 to 70 years of age.

ECOG performance status of 0 or 1.

PART 1: Donor must be a 5/6 or 6/6 HLA-matched sibling willing to donate PBSC for transplant.

PART 2: Donor must be a 5/6 or 6/6 HLA-matched sibling or 3/6 or 4/6 HLA haploidentical donor willing to donate PBSC for transplant. Haploidentical donors will be allowed to participate upon investigator decision and based on the data reached from 5/6 or 6/6 HLA matched transplant done during Part 1 of the study.

Adequate organ function defined by:

* serum creatinine within normal limits or a minimum creatinine clearance (CrCl) value of ≥ 60 ml/min calculated using the Modification of Diet in Renal Disease (MDRD) Study equation

* AST, ALT and total bilirubin ≤ 2x institutional upper limit of normal.

Women of childbearing potential and men must agree to use adequate contraception with two different forms, including one barrier method, during participation in the study and for 2 weeks following dosing with BL-8040. Abstinence is acceptable if this is the established and preferred contraception for the subject.

Female subjects must have a negative urine or serum pregnancy test within 10 days prior to taking study medication if of childbearing potential or must be of non-childbearing potential. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as:

-≥ 45 years of age and has not had menses for \> 2 years

Amenorrheic for \> 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation

Post-hysterectomy, oophorectomy, or tubal ligation.

Able and willing to comply with the requirements of the protocol.

Able to understand and willing to sign an IRB-approved written informed consent document.

Age 18 to 75 years

ECOG performance status of 0-2 (inclusive)

One of the following diagnoses:

* Acute myelogenous leukemia (AML) in 1st or subsequent remission

* Acute lymphoblastic leukemia (ALL) in 1st or subsequent remission

* Chronic myelogenous leukemia (CML) in chronic or accelerated phase

* Non-Hodgkin lymphoma (NHL) or Hodgkin's disease (HD) in 2nd or greater complete remission, partial remission

* Chronic lymphocytic leukemia (CLL)

* Multiple myeloma (MM)

* Myelodysplastic syndrome (MDS)

* Myeloproliferative neoplasm (MPN) excluding primary or secondary myelofibrosis

Adequate organ function defined by:

* a creatinine clearance (CrCl) value of ≥ 60 ml/min by MDRD study equation

* AST, ALT and a total bilirubin ≤ 2x institutional upper limit of normal.

Adequate cardiac function with a left ventricular ejection fraction ≥ 40%.

Adequate pulmonary function defined as NO severe or symptomatic restrictive or obstructive lung disease, and formal pulmonary function testing showing an FEV1 ≥50% of predicted and a DLCO ≥ 40% of predicted, corrected for hemoglobin.

Female subjects must have a negative urine or serum pregnancy test if of childbearing potential or be of non-childbearing potential. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. The serum pregnancy test must be negative for the subject to be eligible. Non-childbearing potential is defined as:

\*≥ 45 years of age and has not had menses for \> 2 years

* Amenorrheic for \> 2 years without a hysterectomy and oophorectomy and a FSH value in the postmenopausal range upon pretrial (screening) evaluation

* Post-hysterectomy, oophorectomy, or tubal ligation.

Able to understand and willing to sign an IRB-approved written informed consent document.

What this study is about